Bristol-Myers Squibb Company
IMPROVED METHODS OF ANTIBODY PRODUCTION THAT MINIMIZE DISULFIDE BOND REDUCTION

Last updated:

Abstract:

The present disclosure discloses methods for purifying antibodies providing an air overlay or headspace to single-use storage bags containing the antibody during purification. In specific embodiments, the application relates to purification of antibodies to human TIGIT (T cell immunoreceptor with Ig and ITIM domains), such as antibody 22G2, which decrease unwanted disulfide bond reduction. The application further provides depth filtration at lower throughput and/or flux, which also minimizes unwanted disulfide bond reduction.

Status:
Application
Type:

Utility

Filling date:

24 Apr 2018

Issue date:

11 Jun 2020